{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T11:58:00Z","timestamp":1790164680193,"version":"4.1.0"},"reference-count":55,"publisher":"Public Library of Science (PLoS)","issue":"6","license":[{"start":{"date-parts":[[2010,6,22]],"date-time":"2010-06-22T00:00:00Z","timestamp":1277164800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosntds.org"],"crossmark-restriction":false},"short-container-title":["PLoS Negl Trop Dis"],"DOI":"10.1371\/journal.pntd.0000725","type":"journal-article","created":{"date-parts":[[2010,6,22]],"date-time":"2010-06-22T19:58:44Z","timestamp":1277236724000},"page":"e725","update-policy":"https:\/\/doi.org\/10.1371\/journal.pntd.corrections_policy","source":"Crossref","is-referenced-by-count":48,"title":["Vaccination with DNA Plasmids Expressing Gn Coupled to C3d or Alphavirus Replicons Expressing Gn Protects Mice against Rift Valley Fever Virus"],"prefix":"10.1371","volume":"4","author":[{"given":"Nitin","family":"Bhardwaj","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark T.","family":"Heise","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ted M.","family":"Ross","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2010,6,22]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1002\/path.1700340418","article-title":"Enzootic hepatitis of Rift Valley fever: an undescribed virus disease of sheep, cattle and man from East Africa.","volume":"34","author":"RJ Daubney","year":"1931","journal-title":"J Pathol Bacteriol"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1086\/378747","article-title":"Rift Valley fever epidemic in Saudi Arabia: epidemiological, clinical, and laboratory characteristics.","volume":"37","author":"TA Madani","year":"2003","journal-title":"Clin Infect Dis"},{"key":"ref3","first-page":"100","article-title":"Rift Valley fever in humans in Egypt: an overview of epizootics in 1977 and 1978.","volume":"3","author":"J Meegan","year":"1981","journal-title":"Contrib Epidemiol Biostat"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/S0923-2516(89)80096-2","article-title":"Analytical study of a Rift Valley fever epidemic.","volume":"140","author":"A Jouan","year":"1989","journal-title":"Res Virol"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.3201\/eid0812.020195","article-title":"Genetic analysis of viruses associated with emergence of Rift Valley fever in Saudi Arabia and Yemen, 2000-01.","volume":"8","author":"T Shoemaker","year":"2002","journal-title":"Emerg Infect Dis"},{"key":"ref6","first-page":"73","article-title":"Rift Valley fever outbreak-Kenya, November 2006\u2013January 2007.","volume":"56","author":"P Nguku","year":"2007","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"ref7","article-title":"Bunyaviridae: The viruses and their replication. Fields' Virology","author":"CS Schmaljohn","year":"2001"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.virol.2006.08.002","article-title":"Synthesis, proteolytic processing and complex formation of N-terminally nested precursor proteins of the Rift Valley fever virus glycoproteins.","volume":"357","author":"SR Gerrard","year":"2007","journal-title":"Virology"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/j.virol.2006.09.035","article-title":"The NSm proteins of Rift Valley fever virus are dispensable for maturation, replication and infection.","volume":"359","author":"SR Gerrard","year":"2007","journal-title":"Virology"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"1538","DOI":"10.1128\/JVI.74.3.1538-1543.2000","article-title":"The S segment of rift valley fever phlebovirus (Bunyaviridae) carries determinants for attenuation and virulence in mice.","volume":"74","author":"P Vialat","year":"2000","journal-title":"J Virol"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"13335","DOI":"10.1128\/JVI.01238-07","article-title":"NSm protein of Rift Valley fever virus suppresses virus-induced apoptosis.","volume":"81","author":"S Won","year":"2007","journal-title":"J Virol"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1128\/CMR.18.4.583-607.2005","article-title":"Current and developing technologies for monitoring agents of bioterrorism and biowarfare.","volume":"18","author":"DV Lim","year":"2005","journal-title":"Clin Microbiol Rev"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/S0264-410X(99)00218-2","article-title":"Immunogenicity of an inactivated Rift Valley fever vaccine in humans: a 12-year experience.","volume":"18","author":"P Pittman","year":"1999","journal-title":"Vaccine"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/0264-410X(86)90007-1","article-title":"Evaluation of a new Rift Valley fever vaccine: safety and immunogenicity trials.","volume":"4","author":"GF Meadors 3rd","year":"1986","journal-title":"Vaccine"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1186\/1743-422X-6-94","article-title":"Pathological studies on postvaccinal reactions of Rift Valley fever in goats.","volume":"6","author":"SA Kamal","year":"2009","journal-title":"Virol J"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1002\/jmv.20624","article-title":"Adverse response of non-indigenous cattle of European breeds to live attenuated Smithburn Rift Valley fever vaccine.","volume":"78","author":"B Botros","year":"2006","journal-title":"J Med Virol"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"2271","DOI":"10.1099\/0022-1317-66-10-2271","article-title":"Mutagen-directed attenuation of Rift Valley fever virus as a method for vaccine development.","volume":"66(Pt 10)","author":"H Caplen","year":"1985","journal-title":"J Gen Virol"},{"key":"ref18","first-page":"95","article-title":"Teratogenicity of a mutagenised Rift Valley fever virus (MVP 12) in sheep.","volume":"69","author":"P Hunter","year":"2002","journal-title":"Onderstepoort J Vet Res"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1089\/dna.2007.0639","article-title":"Immunostimulant adjuvant patch enhances humoral and cellular immune responses to DNA immunization.","volume":"27","author":"M Mkrtichyan","year":"2008","journal-title":"DNA Cell Biol"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"191","DOI":"10.2174\/1570162053506937","article-title":"C3d enhances immune responses using low doses of DNA expressing the HIV-1 envelope from codon-optimized gene sequences.","volume":"3","author":"JF Bower","year":"2005","journal-title":"Curr HIV Res"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"4532","DOI":"10.1016\/S0264-410X(03)00510-3","article-title":"Protection against influenza virus infection by intranasal administration of C3d-fused hemagglutinin.","volume":"21","author":"I Watanabe","year":"2003","journal-title":"Vaccine"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1016\/S0264-410X(02)00539-X","article-title":"Induction of heterosubtypic immunity to influenza A virus using a DNA vaccine expressing hemagglutinin-C3d fusion proteins.","volume":"21","author":"JA Mitchell","year":"2003","journal-title":"Vaccine"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"2046","DOI":"10.1128\/JVI.77.3.2046-2055.2003","article-title":"Enhancement of antibodies to the human immunodeficiency virus type 1 envelope by using the molecular adjuvant C3d.","volume":"77","author":"TD Green","year":"2003","journal-title":"J Virol"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1089\/088922201750252025","article-title":"Enhanced avidity maturation of antibody to human immunodeficiency virus envelope: DNA vaccination with gp120-C3d fusion proteins.","volume":"17","author":"TM Ross","year":"2001","journal-title":"AIDS Res Hum Retroviruses"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1038\/77802","article-title":"C3d enhancement of antibodies to hemagglutinin accelerates protection against influenza virus challenge.","volume":"1","author":"TM Ross","year":"2000","journal-title":"Nat Immunol"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1385\/IR:36:1:197","article-title":"Complement-mediated activation of the adaptive immune responses: role of C3d in linking the innate and adaptive immunity.","volume":"36","author":"FR Toapanta","year":"2006","journal-title":"Immunol Res"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"11677","DOI":"10.1128\/JVI.75.23.11677-11685.2001","article-title":"Individual and bivalent vaccines based on alphavirus replicons protect guinea pigs against infection with Lassa and Ebola viruses.","volume":"75","author":"P Pushko","year":"2001","journal-title":"J Virol"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/j.virol.2007.04.014","article-title":"Comparative analysis of the alphavirus-based vectors expressing Rift Valley fever virus glycoproteins.","volume":"366","author":"R Gorchakov","year":"2007","journal-title":"Virology"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1017\/S0950268808001696","article-title":"An alphavirus replicon-derived candidate vaccine against Rift Valley fever virus.","volume":"137","author":"MT Heise","year":"2009","journal-title":"Epidemiol Infect"},{"key":"ref30","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1126\/science.271.5247.348","article-title":"C3d of complement as a molecular adjuvant: bridging innate and acquired immunity.","volume":"271","author":"PW Dempsey","year":"1996","journal-title":"Science"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1016\/S0264-410X(01)00485-6","article-title":"Alphavirus replicon particles expressing the two major envelope proteins of equine arteritis virus induce high level protection against challenge with virulent virus in vaccinated horses.","volume":"20","author":"UB Balasuriya","year":"2002","journal-title":"Vaccine"},{"key":"ref32","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1016\/0264-410X(95)00069-D","article-title":"Gene gun-based nucleic acid immunization: elicitation of humoral and cytotoxic T lymphocyte responses following epidermal delivery of nanogram quantities of DNA.","volume":"13","author":"TM Pertmer","year":"1995","journal-title":"Vaccine"},{"key":"ref33","first-page":"S43","article-title":"Accell particle-mediated DNA immunization elicits humoral, cytotoxic, and protective immune responses.","volume":"10","author":"JR Haynes","year":"1994","journal-title":"AIDS Res Hum Retroviruses"},{"key":"ref34","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1006\/viro.1999.9666","article-title":"Studies on antibody responses following neonatal immunization with influenza hemagglutinin DNA or protein.","volume":"257","author":"TM Pertmer","year":"1999","journal-title":"Virology"},{"key":"ref35","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1007\/0-387-34134-X_17","article-title":"A minimum CR2 binding domain of C3d enhances immunity following vaccination.","volume":"587","author":"JF Bower","year":"2006","journal-title":"Advances in experimental medicine and biology"},{"key":"ref36","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/S0264-410X(99)00218-2","article-title":"Immunogenicity of an inactivated Rift Valley fever vaccine in humans: a 12-year experience.","volume":"18","author":"PR Pittman","year":"1999","journal-title":"Vaccine"},{"key":"ref37","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1186\/1465-9921-10-112","article-title":"Impaired immune responses in the lungs of aged mice following influenza infection.","volume":"10","author":"FR Toapanta","year":"2009","journal-title":"Respir Res"},{"key":"ref38","doi-asserted-by":"crossref","first-page":"7181","DOI":"10.1016\/j.vaccine.2006.06.041","article-title":"Protective immune responses induced by different recombinant vaccine regimes to Rift Valley fever.","volume":"24","author":"DB Wallace","year":"2006","journal-title":"Vaccine"},{"key":"ref39","doi-asserted-by":"crossref","first-page":"4657","DOI":"10.1016\/j.vaccine.2005.08.034","article-title":"Immunogenicity of combination DNA vaccines for Rift Valley fever virus, tick-borne encephalitis virus, Hantaan virus, and Crimean Congo hemorrhagic fever virus.","volume":"24","author":"K Spik","year":"2006","journal-title":"Vaccine"},{"key":"ref40","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/0042-6822(89)90365-6","article-title":"Baculovirus expression of the M genome segment of Rift Valley fever virus and examination of antigenic and immunogenic properties of the expressed proteins.","volume":"170","author":"CS Schmaljohn","year":"1989","journal-title":"Virology"},{"key":"ref41","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/1743-422X-6-6","article-title":"Characterisation of immune responses and protective efficacy in mice after immunisation with Rift Valley Fever virus cDNA constructs.","volume":"6","author":"N Lagerqvist","year":"2009","journal-title":"Virol J"},{"key":"ref42","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/j.virol.2007.04.014","article-title":"Comparative analysis of the alphavirus-based vectors expressing Rift Valley fever virus glycoproteins.","volume":"366","author":"R Gorchakov","year":"2007","journal-title":"Virology"},{"key":"ref43","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/j.virol.2008.12.012","article-title":"Vaccination with virus-like particles protects mice from lethal infection of Rift Valley Fever Virus.","volume":"385","author":"J Naslund","year":"2009","journal-title":"Virology"},{"key":"ref44","doi-asserted-by":"crossref","first-page":"293","DOI":"10.4049\/jimmunol.93.2.293","article-title":"Immunization against Rift Valley Fever Virus. Studies on the Immunogenicity of Lyophilized Formalin-Inactivated Vaccine.","volume":"93","author":"R Randall","year":"1964","journal-title":"J Immunol"},{"key":"ref45","doi-asserted-by":"crossref","first-page":"50","DOI":"10.2460\/ajvr.1991.52.01.50","article-title":"Ability of a mutagenized virus variant to protect young lambs from Rift Valley fever.","volume":"52","author":"KA Hubbard","year":"1991","journal-title":"Am J Vet Res"},{"key":"ref46","first-page":"179","article-title":"Veterinary vaccines and their use in developing countries.","volume":"26","author":"J Lubroth","year":"2007","journal-title":"Rev Sci Tech"},{"key":"ref47","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/S0168-1656(99)00121-2","article-title":"Diva vaccines that reduce virus transmission.","volume":"73","author":"JT van Oirschot","year":"1999","journal-title":"J Biotechnol"},{"key":"ref48","doi-asserted-by":"crossref","first-page":"2681","DOI":"10.1128\/JVI.02501-07","article-title":"Rift valley fever virus lacking the NSs and NSm genes is highly attenuated, confers protective immunity from virulent virus challenge, and allows for differential identification of infected and vaccinated animals.","volume":"82","author":"BH Bird","year":"2008","journal-title":"J Virol"},{"key":"ref49","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.jviromet.2006.11.005","article-title":"Preparation and evaluation of a recombinant Rift Valley fever virus N protein for the detection of IgG and IgM antibodies in humans and animals by indirect ELISA.","volume":"140","author":"P Jansen van Vuren","year":"2007","journal-title":"J Virol Methods"},{"key":"ref50","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.jviromet.2008.04.007","article-title":"Kinetics of Rift Valley Fever Virus in experimentally infected mice using quantitative real-time RT-PCR.","volume":"151","author":"J Naslund","year":"2008","journal-title":"J Virol Methods"},{"key":"ref51","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.jviromet.2005.07.002","article-title":"Production of monoclonal antibodies against Rift Valley fever virus Application for rapid diagnosis tests (virus detection and ELISA) in human sera.","volume":"131","author":"A Zaki","year":"2006","journal-title":"J Virol Methods"},{"key":"ref52","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1038\/nrg2432","article-title":"DNA vaccines: ready for prime time?","volume":"9","author":"MA Kutzler","year":"2008","journal-title":"Nat Rev Genet"},{"key":"ref53","doi-asserted-by":"crossref","first-page":"2120","DOI":"10.1016\/j.vaccine.2006.11.016","article-title":"Studies of a prophylactic HIV-1 vaccine candidate based on modified vaccinia virus Ankara (MVA) with and without DNA priming: effects of dosage and route on safety and immunogenicity.","volume":"25","author":"BS Peters","year":"2007","journal-title":"Vaccine"},{"key":"ref54","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1128\/JVI.58.2.263-270.1986","article-title":"Use of bacterial expression cloning to define the amino acid sequences of antigenic determinants on the G2 glycoprotein of Rift Valley fever virus.","volume":"58","author":"K Keegan","year":"1986","journal-title":"J Virol"},{"key":"ref55","doi-asserted-by":"crossref","first-page":"5255","DOI":"10.1016\/j.vaccine.2008.07.042","article-title":"Priming with DNA plasmids encoding the nucleocapsid protein and glycoprotein precursors from Rift Valley fever virus accelerates the immune responses induced by an attenuated vaccine in sheep.","volume":"26","author":"G Lorenzo","year":"2008","journal-title":"Vaccine"}],"container-title":["PLoS Neglected Tropical Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pntd.0000725","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,27]],"date-time":"2024-03-27T19:23:11Z","timestamp":1711567391000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pntd.0000725"}},"subtitle":[],"editor":[{"given":"Daniel G.","family":"Bausch","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2010,6,22]]},"references-count":55,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2010,6,22]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pntd.0000725","relation":{},"ISSN":["1935-2735"],"issn-type":[{"value":"1935-2735","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,6,22]]}}}